BRAF V600E 突变在结直肠癌（CRC）中是一个重要的生物标志物，约占所有结直肠癌病例的 10%。这一突变通常与肿瘤的侵袭性、预后不良以及对常规化疗的耐药性相关联 [1] 。研究显示，BRAF V600E 突变导致肿瘤细胞激活 MAPK 信号通路，进而快速增殖和转移，使得患者的 ...

BRAF V600E 突变在结直肠癌（CRC）中是一个重要的生物标志物，约占所有结直肠癌病例的 10%。这一突变通常与肿瘤的侵袭性、预后不良以及对常规化疗 ...

BRAF V600E-mutant metastatic CRC is associated with poor clinical outcomes, with a median overall survival of 17 months. Factors influencing overall survival include metastasectomy and ECOG ...

Referring to a case of a patient, age 41, with BRAF V600E-mutated proficient mismatch repair, microsatellite stable (pMMR/MSS) CRC, Messersmith said that instead of waiting for second- or third ...

For 20% of those diagnosed with CRC, the disease has metastasized, or spread, making it harder to treat, and up to 50% of patients with localized disease eventually develop metastases. BRAF mutations ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...

OS is a key secondary endpoint. BRAFTOVI is an oral small molecule kinase inhibitor that targets BRAF V600E . Inappropriate activation of proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK) has ...

Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of this combination by the Food and Drug Administration (FDA) in Dec. 2024, providing an ...

Braftovi combo improved objective response rate to 60.9% vs. 40% with standard chemotherapy in BRAF V600E-mutant mCRC. Median response duration was 13.9 months vs. 11.1 months, with 22.4% ...